Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-5013 (Lenalidomide) in Metastatic Malignant Melanoma
NCT00055562Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lenalidomide in melanoma, sponsored by Celgene Corporation. Started Jan 2003; status: completed.
02
Drugs
lenalidomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00055562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055562.